LCTXNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Lineage Cell Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$0.95−0.03 (-2.61%)

Close on Oct 19, 2026

Community

Notes and questions about Lineage Cell Therapeutics from other investors

Discussion opens with sign-in. Posts will be able to point at any number on these pages, so everyone sees exactly which figure is being discussed.

Parsed from the XBRL in Lineage Cell Therapeutics's annual and quarterly filings with the SEC
Per-share figures adjusted for the 3-for-1 split on Oct 31, 1997
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is LCTX.

Revenue growth19.9% · median -10.0%

Operating margin-205.2% · median -1090.9%

Net margin-246.6% · median -1061.1%

Advertisement
300 × 250